
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech is viewed favorably because its lead asset, Ampligen, is being tested in combination with checkpoint blockade therapies at multiple major U.S. cancer research centers, creating several shots on goal across oncology indications. The company’s investment case is strengthened by positive initial and recent trial data, with additional clinical readouts expected over the next year, which could further validate efficacy, improve tumor response and survival metrics, and serve as meaningful catalysts. Despite development timelines of roughly 2 years to 3 years and substantial execution risk, the potential for billion-dollar market opportunities and an attractive NPV-based valuation supports an optimistic fundamental outlook.
Bears say
AIM ImmunoTech is a clinical-stage biotech with minimal revenue, and its fundamentals remain weak because it has not yet proven it can convert its pipeline into commercial cash flow. In Q2 2026, it posted a $7 million net loss, or $(0.43) per share, and in Q1 2026 it lost $3.0 million, or $(0.69) per share, underscoring persistent losses despite no guidance and limited operating visibility. The outlook is negative because the company still faces balance sheet and liquidity risk, plus major binary uncertainties around clinical safety, efficacy, regulatory approval, reimbursement, and commercialization.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares